当代Fontan手术结局:大型单中心队列研究
该单中心队列纳入1995至2016年610例Fontan手术患者,中位手术年龄4岁,中位随访6.8年。围术期死亡率为0.5%,5年、10年、15年无移植生存率分别为97%、94%、92%,无失败生存率分别为91%、89%、87%。遗传综合征、心室功能障碍、体外循环时间和持续性胸腔积液是慢性失败的独立危险因素。
要点
- 当代Fontan手术围术期死亡率低(0.5%),中远期无移植生存率良好。
- 手术室内拔管与急性失败风险降低相关(OR 0.30)。
- 遗传综合征、心室功能障碍、体外循环时间及持续性胸腔积液增加慢性失败风险。
核心结论
- 当代Fontan患者中期结局良好,围术期死亡率为0.5%,5年、10年、15年无移植生存率分别为97%、94%、92%。
- 需终身随访以确定长期结局及成年后额外手术需求。
研究设计与样本
- 单中心回顾性队列研究,纳入1995至2016年所有接受Fontan手术的患者,共610例。
- 中位手术年龄4岁,中位随访6.8年。
- 采用多因素logistic回归和Cox回归模型识别急性(围术期)和慢性失败的危险因素。
主要发现
- 围术期死亡3例(0.5%)。
- 5年、10年、15年无移植生存率分别为97%、94%、92%;无失败生存率分别为91%、89%、87%。
- 手术室内拔管与急性失败风险降低相关(OR 0.30,95%CI 0.11-0.87)。
- 慢性失败独立危险因素包括:遗传综合征(HR 2.54,95%CI 1.11-5.83)、心室功能障碍(HR 3.86,95%CI 1.81-8.24)、体外循环时间每30分钟(HR 1.242,95%CI 1.100-1.402)、持续性胸腔积液(HR 4.26,95%CI 2.25-8.07)。
- 中重度房室瓣反流(HR 2.61,95%CI 1.13-6.02)和体外循环时间(HR 1.22,95%CI 1.03-1.45)与无移植生存率降低相关。
临床怎么用
- 关注手术室内拔管以降低急性失败风险。
- 对合并遗传综合征、心室功能障碍、长体外循环时间或持续性胸腔积液的患者加强随访。
- 中重度房室瓣反流患者需密切监测长期生存。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 中位随访6.8年,长期结局尚需更长时间随访确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Fontan procedure is the accepted standard for single-ventricle palliation. The goal of this study was to determine short- and midterm outcomes of patients undergoing a Fontan operation at a single institution and to identify contemporary risk factors for acute and chronic failure. METHODS: All patients undergoing a Fontan operation between 1995 and 2016 were included. Failure was defined as death, transplantation, Fontan takedown or revision, fenestration creation or enlargement, plastic bronchitis, protein-losing enteropathy, or major perioperative reintervention. Multivariable logistic and Cox regression models were used to identify risk factors for acute (perioperative) and chronic failure (after hospital discharge or 30 days postoperatively, or both). RESULTS: The cohort included 610 patients. Median age at surgery was 4 years. Median follow-up was 6.8 years. Trends showed increasing use of extracardiac conduits, nonfenestrated Fontan, and extubation in the operating room. Perioperative mortality was 0.5% (n = 3). Transplant-free survival at 5, 10, and 15 years was 97%, 94%, and 92%, respectively; freedom from failure was 91%, 89%, and 87%, respectively. Extubation in the operating room was associated with lower risk of acute failure (odds ratio, 0.30; 95% confidence interval [CI], 0.11 to 0.87). Independent risk factors for chronic failure included genetic syndrome (hazard ratio [HR], 2.54; 95% CI, 1.11 to 5.83), ventricular dysfunction (HR, 3.86; 95% CI, 1.81 to 8.24), cardiopulmonary bypass time in 30-minute intervals (HR, 1.242; 95% CI, 1.100 to 1.402), and persistent pleural effusions (HR, 4.26; 95% CI, 2.25 to 8.07). Moderate or severe atrioventricular valve regurgitation (HR, 2.61; 95% CI, 1.13 to 6.02) and cardiopulmonary bypass time (HR, 1.22; 95% CI, 1.03 to 1.45) were associated with reduced long-term transplant-free survival. CONCLUSIONS: Contemporary midterm outcomes for Fontan patients are reassuring. Lifelong follow-up is mandatory to determine long-term outcomes and need for additional surgery as patients reach adulthood.
引用
- Mery CM, De León LE, Trujillo-Diaz D, et al. Contemporary Outcomes of the Fontan Operation: A Large Single-Institution Cohort. Ann Thorac Surg. 2019. PMID: 31279788. doi:10.1016/j.athoracsur.2019.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。